Table of Content

1 Oculopharyngeal Muscular Dystrophy (OPMD) Market Overview
1.1 Product Overview and Scope of Oculopharyngeal Muscular Dystrophy (OPMD)
1.2 Oculopharyngeal Muscular Dystrophy (OPMD) Segment by Type
1.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Value Comparison by Type (2024-2034)
1.2.2 Tablets
1.2.3 Capsules
1.2.4 Injectable
1.2.5 Other
1.3 Oculopharyngeal Muscular Dystrophy (OPMD) Segment by Application
1.3.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Value by Application: (2024-2034)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size Estimates and Forecasts
1.4.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue 2018-2034
1.4.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales 2018-2034
1.4.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 Oculopharyngeal Muscular Dystrophy (OPMD) Market Competition by Manufacturers
2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Manufacturers (2018-2023)
2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Average Price by Manufacturers (2018-2023)
2.4 Global Oculopharyngeal Muscular Dystrophy (OPMD) Industry Ranking 2021 VS 2024 VS 2023
2.5 Global Key Manufacturers of Oculopharyngeal Muscular Dystrophy (OPMD), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oculopharyngeal Muscular Dystrophy (OPMD), Product Type & Application
2.7 Oculopharyngeal Muscular Dystrophy (OPMD) Market Competitive Situation and Trends
2.7.1 Oculopharyngeal Muscular Dystrophy (OPMD) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Oculopharyngeal Muscular Dystrophy (OPMD) Players Market Share by Revenue
2.7.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Oculopharyngeal Muscular Dystrophy (OPMD) Retrospective Market Scenario by Region
3.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Region: 2018 Versus 2024 Versus 2034
3.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region: 2018-2034
3.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region: 2018-2023
3.2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region: 2024-2034
3.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region: 2018-2034
3.3.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region: 2018-2023
3.3.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region: 2024-2034
3.4 North America Oculopharyngeal Muscular Dystrophy (OPMD) Market Facts & Figures by Country
3.4.1 North America Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Country: 2018 VS 2024 VS 2034
3.4.2 North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2034)
3.4.3 North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Market Facts & Figures by Country
3.5.1 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Country: 2018 VS 2024 VS 2034
3.5.2 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2034)
3.5.3 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Market Facts & Figures by Country
3.6.1 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Country: 2018 VS 2024 VS 2034
3.6.2 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2034)
3.6.3 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Market Facts & Figures by Country
3.7.1 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Country: 2018 VS 2024 VS 2034
3.7.2 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2034)
3.7.3 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Market Facts & Figures by Country
3.8.1 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Country: 2018 VS 2024 VS 2034
3.8.2 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2034)
3.8.3 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type (2018-2034)
4.1.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type (2018-2023)
4.1.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Type (2024-2034)
4.1.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Type (2018-2034)
4.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Type (2018-2034)
4.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Type (2018-2023)
4.2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Type (2024-2034)
4.2.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Type (2018-2034)
4.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Price by Type (2018-2034)
5 Segment by Application
5.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application (2018-2034)
5.1.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application (2018-2023)
5.1.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Application (2024-2034)
5.1.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Application (2018-2034)
5.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Application (2018-2034)
5.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Application (2018-2023)
5.2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Application (2024-2034)
5.2.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Application (2018-2034)
5.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Price by Application (2018-2034)
6 Key Companies Profiled
6.1 Benitec Biopharma Inc.
6.1.1 Benitec Biopharma Inc. Corporation Information
6.1.2 Benitec Biopharma Inc. Description and Business Overview
6.1.3 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
6.1.5 Benitec Biopharma Inc. Recent Developments/Updates
6.2 Bioblast Pharma
6.2.1 Bioblast Pharma Corporation Information
6.2.2 Bioblast Pharma Description and Business Overview
6.2.3 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
6.2.5 Bioblast Pharma Recent Developments/Updates
6.3 BioMarin
6.3.1 BioMarin Corporation Information
6.3.2 BioMarin Description and Business Overview
6.3.3 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2018-2023)
6.3.4 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
6.3.5 BioMarin Recent Developments/Updates
6.4 PTC Therapeutics
6.4.1 PTC Therapeutics Corporation Information
6.4.2 PTC Therapeutics Description and Business Overview
6.4.3 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
6.4.5 PTC Therapeutics Recent Developments/Updates
6.5 NS Pharma
6.5.1 NS Pharma Corporation Information
6.5.2 NS Pharma Description and Business Overview
6.5.3 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2018-2023)
6.5.4 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
6.5.5 NS Pharma Recent Developments/Updates
6.6 Nobelpharma Co., Ltd
6.6.1 Nobelpharma Co., Ltd Corporation Information
6.6.2 Nobelpharma Co., Ltd Description and Business Overview
6.6.3 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
6.6.5 Nobelpharma Co., Ltd Recent Developments/Updates
6.7 Santhera Pharmaceuticals
6.6.1 Santhera Pharmaceuticals Corporation Information
6.6.2 Santhera Pharmaceuticals Description and Business Overview
6.6.3 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
6.7.5 Santhera Pharmaceuticals Recent Developments/Updates
6.8 Pfizer Inc.
6.8.1 Pfizer Inc. Corporation Information
6.8.2 Pfizer Inc. Description and Business Overview
6.8.3 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
6.8.5 Pfizer Inc. Recent Developments/Updates
6.9 Marathon Pharmaceuticals
6.9.1 Marathon Pharmaceuticals Corporation Information
6.9.2 Marathon Pharmaceuticals Description and Business Overview
6.9.3 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
6.9.5 Marathon Pharmaceuticals Recent Developments/Updates
6.10 Fibrogen
6.10.1 Fibrogen Corporation Information
6.10.2 Fibrogen Description and Business Overview
6.10.3 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
6.10.5 Fibrogen Recent Developments/Updates
6.11 Bristol-Myers Squibb
6.11.1 Bristol-Myers Squibb Corporation Information
6.11.2 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Description and Business Overview
6.11.3 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
6.11.5 Bristol-Myers Squibb Recent Developments/Updates
6.12 Sarepta Therapeutics
6.12.1 Sarepta Therapeutics Corporation Information
6.12.2 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Description and Business Overview
6.12.3 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
6.12.5 Sarepta Therapeutics Recent Developments/Updates
6.13 GSK
6.13.1 GSK Corporation Information
6.13.2 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Description and Business Overview
6.13.3 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2018-2023)
6.13.4 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
6.13.5 GSK Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oculopharyngeal Muscular Dystrophy (OPMD) Industry Chain Analysis
7.2 Oculopharyngeal Muscular Dystrophy (OPMD) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oculopharyngeal Muscular Dystrophy (OPMD) Production Mode & Process
7.4 Oculopharyngeal Muscular Dystrophy (OPMD) Sales and Marketing
7.4.1 Oculopharyngeal Muscular Dystrophy (OPMD) Sales Channels
7.4.2 Oculopharyngeal Muscular Dystrophy (OPMD) Distributors
7.5 Oculopharyngeal Muscular Dystrophy (OPMD) Customers
8 Oculopharyngeal Muscular Dystrophy (OPMD) Market Dynamics
8.1 Oculopharyngeal Muscular Dystrophy (OPMD) Industry Trends
8.2 Oculopharyngeal Muscular Dystrophy (OPMD) Market Drivers
8.3 Oculopharyngeal Muscular Dystrophy (OPMD) Market Challenges
8.4 Oculopharyngeal Muscular Dystrophy (OPMD) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Competitive Situation by Manufacturers in 2024
Table 4. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Oculopharyngeal Muscular Dystrophy (OPMD) Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Oculopharyngeal Muscular Dystrophy (OPMD), Industry Ranking, 2021 VS 2024 VS 2023
Table 10. Global Key Manufacturers of Oculopharyngeal Muscular Dystrophy (OPMD), Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Oculopharyngeal Muscular Dystrophy (OPMD), Product Type & Application
Table 12. Global Key Manufacturers of Oculopharyngeal Muscular Dystrophy (OPMD), Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Oculopharyngeal Muscular Dystrophy (OPMD) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oculopharyngeal Muscular Dystrophy (OPMD) as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 17. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2018-2023) & (K Units)
Table 18. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Region (2018-2023)
Table 19. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2024-2034) & (K Units)
Table 20. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Region (2024-2034)
Table 21. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Region (2018-2023)
Table 23. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Region (2024-2034)
Table 25. North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 26. North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2023) & (K Units)
Table 27. North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2024-2034) & (K Units)
Table 28. North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 31. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2023) & (K Units)
Table 32. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2024-2034) & (K Units)
Table 33. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 36. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 41. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 46. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units) by Type (2018-2023)
Table 51. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units) by Type (2024-2034)
Table 52. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Type (2018-2023)
Table 53. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Type (2024-2034)
Table 54. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Type (2018-2023)
Table 57. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Type (2024-2034)
Table 58. Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (US$/Unit) by Type (2018-2023)
Table 59. Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (US$/Unit) by Type (2024-2034)
Table 60. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units) by Application (2018-2023)
Table 61. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units) by Application (2024-2034)
Table 62. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Application (2018-2023)
Table 63. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Application (2024-2034)
Table 64. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Application (2018-2023)
Table 67. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Application (2024-2034)
Table 68. Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (US$/Unit) by Application (2018-2023)
Table 69. Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (US$/Unit) by Application (2024-2034)
Table 70. Benitec Biopharma Inc. Corporation Information
Table 71. Benitec Biopharma Inc. Description and Business Overview
Table 72. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product
Table 74. Benitec Biopharma Inc. Recent Developments/Updates
Table 75. Bioblast Pharma Corporation Information
Table 76. Bioblast Pharma Description and Business Overview
Table 77. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product
Table 79. Bioblast Pharma Recent Developments/Updates
Table 80. BioMarin Corporation Information
Table 81. BioMarin Description and Business Overview
Table 82. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Product
Table 84. BioMarin Recent Developments/Updates
Table 85. PTC Therapeutics Corporation Information
Table 86. PTC Therapeutics Description and Business Overview
Table 87. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product
Table 89. PTC Therapeutics Recent Developments/Updates
Table 90. NS Pharma Corporation Information
Table 91. NS Pharma Description and Business Overview
Table 92. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product
Table 94. NS Pharma Recent Developments/Updates
Table 95. Nobelpharma Co., Ltd Corporation Information
Table 96. Nobelpharma Co., Ltd Description and Business Overview
Table 97. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Product
Table 99. Nobelpharma Co., Ltd Recent Developments/Updates
Table 100. Santhera Pharmaceuticals Corporation Information
Table 101. Santhera Pharmaceuticals Description and Business Overview
Table 102. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product
Table 104. Santhera Pharmaceuticals Recent Developments/Updates
Table 105. Pfizer Inc. Corporation Information
Table 106. Pfizer Inc. Description and Business Overview
Table 107. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product
Table 109. Pfizer Inc. Recent Developments/Updates
Table 110. Marathon Pharmaceuticals Corporation Information
Table 111. Marathon Pharmaceuticals Description and Business Overview
Table 112. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product
Table 114. Marathon Pharmaceuticals Recent Developments/Updates
Table 115. Fibrogen Corporation Information
Table 116. Fibrogen Description and Business Overview
Table 117. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Product
Table 119. Fibrogen Recent Developments/Updates
Table 120. Bristol-Myers Squibb Corporation Information
Table 121. Bristol-Myers Squibb Description and Business Overview
Table 122. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Product
Table 124. Bristol-Myers Squibb Recent Developments/Updates
Table 125. Sarepta Therapeutics Corporation Information
Table 126. Sarepta Therapeutics Description and Business Overview
Table 127. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product
Table 129. Sarepta Therapeutics Recent Developments/Updates
Table 130. GSK Corporation Information
Table 131. GSK Description and Business Overview
Table 132. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Product
Table 134. GSK Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Oculopharyngeal Muscular Dystrophy (OPMD) Distributors List
Table 138. Oculopharyngeal Muscular Dystrophy (OPMD) Customers List
Table 139. Oculopharyngeal Muscular Dystrophy (OPMD) Market Trends
Table 140. Oculopharyngeal Muscular Dystrophy (OPMD) Market Drivers
Table 141. Oculopharyngeal Muscular Dystrophy (OPMD) Market Challenges
Table 142. Oculopharyngeal Muscular Dystrophy (OPMD) Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Oculopharyngeal Muscular Dystrophy (OPMD)
Figure 2. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Share by Type in 2024 & 2034
Figure 4. Tablets Product Picture
Figure 5. Capsules Product Picture
Figure 6. Injectable Product Picture
Figure 7. Other Product Picture
Figure 8. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 9. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Share by Application in 2024 & 2034
Figure 10. Hospital Pharmacies
Figure 11. Retail Pharmacies
Figure 12. Online Pharmacies
Figure 13. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 14. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size (2018-2034) & (US$ Million)
Figure 15. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (2018-2034) & (K Units)
Figure 16. Global Oculopharyngeal Muscular Dystrophy (OPMD) Average Price (US$/Unit) & (2018-2034)
Figure 17. Oculopharyngeal Muscular Dystrophy (OPMD) Report Years Considered
Figure 18. Oculopharyngeal Muscular Dystrophy (OPMD) Sales Share by Manufacturers in 2024
Figure 19. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share by Manufacturers in 2024
Figure 20. The Global 5 and 10 Largest Oculopharyngeal Muscular Dystrophy (OPMD) Players: Market Share by Revenue in 2024
Figure 21. Oculopharyngeal Muscular Dystrophy (OPMD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2024
Figure 22. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Figure 23. North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country (2018-2034)
Figure 24. North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country (2018-2034)
Figure 25. United States Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 26. Canada Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 27. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country (2018-2034)
Figure 28. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country (2018-2034)
Figure 29. Germany Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 30. France Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 31. U.K. Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 32. Italy Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 33. Russia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 34. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Region (2018-2034)
Figure 35. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Region (2018-2034)
Figure 36. China Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 37. Japan Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 38. South Korea Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. India Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 40. Australia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 41. China Taiwan Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 42. Indonesia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 43. Thailand Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 44. Malaysia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country (2018-2034)
Figure 46. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country (2018-2034)
Figure 47. Mexico Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 48. Brazil Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 49. Argentina Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 50. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country (2018-2034)
Figure 51. Middle East & Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country (2018-2034)
Figure 52. Turkey Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 53. Saudi Arabia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 54. UAE Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 55. Global Sales Market Share of Oculopharyngeal Muscular Dystrophy (OPMD) by Type (2018-2034)
Figure 56. Global Revenue Market Share of Oculopharyngeal Muscular Dystrophy (OPMD) by Type (2018-2034)
Figure 57. Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (US$/Unit) by Type (2018-2034)
Figure 58. Global Sales Market Share of Oculopharyngeal Muscular Dystrophy (OPMD) by Application (2018-2034)
Figure 59. Global Revenue Market Share of Oculopharyngeal Muscular Dystrophy (OPMD) by Application (2018-2034)
Figure 60. Global Oculopharyngeal Muscular Dystrophy (OPMD) Price (US$/Unit) by Application (2018-2034)
Figure 61. Oculopharyngeal Muscular Dystrophy (OPMD) Value Chain
Figure 62. Oculopharyngeal Muscular Dystrophy (OPMD) Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed